Drug Trial Radar · NCT06549114
Leniolisib for Immune Dysregulation in PIDs
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
13
Actual
Start
Oct 21, 2024
Primary completion
Jun 23, 2026
Study completion Jun 23, 2026
Sponsor
- Lead sponsor
- Pharming Technologies B.V.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an exploratory, non-randomized, open-label, within-patient dose escalation study. The primary objective is to assess safety and tolerability of leniolisib. Secondary objectives include assessments of PK/PD, and to explore clinical efficacy measures with administration of three different dose levels of leniolisib.
Conditions
- Primary Immunodeficiency Disorders (PIDs)
Interventions
LeniolisibDrug
The doses selected will range from 10 to 70 mg twice daily (BID) (resulting in total daily doses ranging from 20 to 140 mg per day).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent adverse events (TEAEs), Serious Adverse Events (SAEs) , and Adverse Events (AEs)Time frame: From Baseline to the end of 20 weeks of Treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Institute of Health
Bethesda, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.